The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy
Cancer Research and Treatment. 2019;51(1):169-177 
Monoclonal Antibodies Versus Tyrosine Kinase Inhibitors Concurrent with Chemotherapy in Non–Small-Cell Lung Cancer: Exploring Divergent Results
Clinical Lung Cancer. 2008;9(3):141-143
Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis
Medical Oncology. 2015;32(2):
Comparison of alternating to nonalternating chemotherapy regimens for non-small cell lung cancer
Lung Cancer. 1987;3(1):50
A three-armed randomized trial in small cell lung cancer (SCLC) of two induction regimens with teniposide and cisplatin or carboplatin followed by alternating chemotherapy versus alternating chemotherapy
Lung Cancer. 1991;7:121
Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer
OncoTargets and Therapy. 2015;13
Second-Generation Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
Clinical Lung Cancer. 2007;8:S50-S51
Chemotherapy of advanced non-small-cell lung cancer: A randomized trial of three cis-platin-based chemotherapy regimens
Lung Cancer. 1990;6(1-2):58
INCIDENCE OF HEPATITIS B REACTIVATION DURING EGFR TYROSINE KINASE INHIBITORS TREATMENT IN NON-SMALL-CELL LUNG CANCER PATIENTS
Respirology. 2018;23:291-291
A randomised trial of two cisplatin-containing chemotherapy regimens in patients with Stage III-B and IV non-small cell lung cancer
Lung Cancer. 1995;13(3):350